Exact Sciences
EXAS
$50.38
Share price
-3.02%
Change (1 day)
-39.43%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
Exact Sciences (EXAS) - P/B ratio
P/B ratio as of May 2024 : 2.96
According to Exact Sciences's latest financial reports the company has a price-to-book ratio of 2.96.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Exact Sciences - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 4.25 | 47.15% |
| 2022-12-31 | 2.89 | -27.55% |
| 2021-12-31 | 3.99 | -55.24% |
| 2020-12-31 | 8.91 | 49.41% |
| 2019-12-31 | 5.97 | -47.73% |
| 2018-12-31 | 11.4 | -5.56% |
| 2017-12-31 | 12.1 | 179.83% |
| 2016-12-31 | 4.32 | 58.23% |
| 2015-12-31 | 2.73 | -67.56% |
| 2014-12-31 | 8.42 | 36.36% |
| 2013-12-31 | 6.17 | -10.1% |
| 2012-12-31 | 6.86 | 33.36% |
| 2011-12-31 | 5.15 | 31.61% |
| 2010-12-31 | 3.91 | -80.21% |
| 2009-12-31 | 19.8 | -409.56% |
| 2008-12-31 | -6.38 | -145.93% |
| 2007-12-31 | 13.9 | 174.32% |
| 2006-12-31 | 5.07 | 113.5% |
| 2005-12-31 | 2.37 | -10.47% |
| 2004-12-31 | 2.65 | -83.41% |
| 2003-12-31 | 16.0 | 196.69% |
| 2002-12-31 | 5.39 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 1.48 | -49.78% | 🇫🇷 France |
 Veracyte VCYT | 1.68 | -43.32% | 🇺🇸 USA |
 Myriad Genetics MYGN | 2.92 | -1.12% | 🇺🇸 USA |
 Biocept
BIOC | 3.94 | 33.24% | 🇺🇸 USA |